C hemokines, acting through various mechanisms including the recruitment of immune cells and smooth muscle progenitor cells (SPCs) to the vessel wall, 1,2 are crucial for vascular remodeling and atherosclerosis. In addition, chemokines are critical for monocyte and neutrophil homeostasis. Hyperlipidemia-induced monocytosis results from the combined action of various chemokine receptors, such as CCR2, which are expressed by immune cells (including monocytes), and facilitates atherosclerosis.
CXCR7 binds to both CXCL12 and CXCL11 and promotes the growth and adhesion of tumor cells. 11, 12 Genetic deletion of Cxcr7 in mice results in a high level of perinatal lethality and abnormal cardiovascular development. 13, 14 In contrast to other chemokine receptors, CXCR7 is not expressed on leukocytes. 15 Although structurally characterized as a G-protein-coupled receptor, CXCR7 does not induce classic G-protein-coupled receptor signaling events but can trigger the recruitment of β-arrestin-2, which leads to receptor internalization or activation of downstream signaling pathways, for example, mitogen-activated protein kinases. 16, 17 The interaction between CXCR7 and β-arrestin-2 controls the bioavailability of extracellular CXCL12. 18, 19 Furthermore, cross-regulation of CXCR4 by CXCR7 can affect CXCR4-dependent Gα i protein activation. 13, 20 Interestingly, the highly selective synthetic CXCR7 ligand CCX771 antagonizes the binding of CXCL12 to CXCR7 but induces the association of β-arrestin-2 with CXCR7 more effectively than its endogenous ligands. 16 In light of this complex interplay between CXCL12, CXCR4, and CXCR7, we aimed to dissect the role played by CXCR7 during vascular remodeling and atherosclerosis and to assess the potential interactions between CXCR7 and the CXCL12/CXCR4 axis in vascular disease.
Here, we identify a key role for CXCR7 in the regulation of serum cholesterol levels by enhancing the uptake of very low-density lipoprotein (VLDL) and increasing the uptake of cholesterol in adipose tissue. The cholesterol-lowering effect of CXCR7 was associated with a reduction in hyperlipidemiainduced monocytosis and with decreased arterial lesion formation and macrophage accumulation.
Methods

Mice
Cxcr7
LacZ/+ and Cxcr7 flox mice (generated on a pure C57Bl/6 background) were provided by ChemoCentryx, Inc (Mountain View, CA). 15 mice fed a high-cholesterol diet (HCD; 21% fat and 0.15% cholesterol; Altromin, Lage, Germany), as described previously. 7 Diet-induced atherosclerosis was induced by feeding Apoe −/− mice an HCD for 12 weeks. Treatment with CCX771 (ChemoCentryx, Inc.) was given via a daily subcutaneous injection (10 mg·kg −1 ·d −1 dissolved in 10% Captisol [Ligand Pharmaceuticals, La Jolla, CA]; 100 μL per injection). Control mice were injected with Captisol alone (10%; 100 μL/mouse SC). Mice expressing tamoxifen-inducible Cre recombinase and the floxed Cxcr7 allele, as well as corresponding control mice, were treated with tamoxifen (1.5 mg per 20 g of body weight; Sigma-Aldrich Chemie GmbH, Munich, Germany) dissolved in neutral oil (Migyol, Sasol Germany GmbH, Hamburg, Germany) for 5 consecutive days (intraperitoneal injection). Wire injury of the carotid arteries was performed 15 days after the last injection of tamoxifen. One week before vascular injury, splenectomy was performed in some Apoe −/− mice after ligation of the splenic vessels. Bone marrow (BM) cells were harvested from femurs of The aorta and carotid arteries were harvested after in situ perfusion fixation with 4% paraformaldehyde (Carl Roth GmbH, Karlsruhe, Germany) or PAXgene (Qiagen GmbH, Hilden, Germany). All animal experiments were reviewed and approved by the local authorities (NRW LANUV [State Agency for Nature, Environment, and Consumer Protection of North Rhein-Westphalia]) according to German animal protection laws.
Histomorphometry
Serial (4 μm thick) cross sections of the left common carotid arteries (within a standardized distance [80-320 μm] from the bifurcation) and the aortic roots were obtained and subsequently stained with modified Movat pentachrome or elastic van Gieson stain (4-6 sections per mouse). Lesions and medial areas were determined by planimetry of digitized images with Diskus software (Hilgers, Königswinter, Germany). The thoracoabdominal aortas were prepared en face and stained with oil red O. The oil red O-stained area and total aortic surface area were quantified with ImageJ software.
Immunostaining
Expression of CXCR7 was studied in 4% paraformaldehyde-fixed cryosections after antigen retrieval with citrate buffer (20 minutes heating in a microwave oven) by incubation with an antibody against CXCR7 (clone 11G8, a gift from ChemoCentryx, Inc). A secondary fluorescein isothiocyanate-conjugated anti-mouse antibody (polyclonal goat; Jackson ImmunoResearch Europe Ltd, Suffolk, United Kingdom) was used to visualize the primary antibody. Sections from Cxcr7 −/− mice were used for negative control staining. The composition of the lesions was determined by immunostaining of α-smooth muscle actin (α-SMA; clone 1A4; Dako Deutschland GmbH, Hamburg, Germany) and macrophage-specific Mac2 (clone M3/38; Cedarlane, Burlington, Canada) in paraffinembedded carotid arteries and aortic roots. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Vectashield, Vector Laboratories, Burlingame, CA). Nonspecific antibodies (Santa Cruz Biotechnology, Dallas, TX) were used for negative control staining. A secondary DyLight 594-, fluorescein isothiocyanate-, or Cy3-conjugated antibody (polyclonal goat; Jackson ImmunoResearch Europe Ltd) was used to visualize the primary antibody. Digital images from ≥4 sections per mouse were recorded with a fluorescence microscope (Leica DM 2500; Leica Microsystems GmbH, Wetzlar, Germany) equipped with a charge-coupled device camera (JVC Deutschland GmbH, Friedberg, Germany) with Diskus software. The numbers of Mac2-stained macrophages and α-SMA-stained smooth muscle cells (SMCs) within the lesions were determined by counting the number of nuclei surrounded by positive staining for Mac2 and α-SMA, respectively.
Statistical Analysis
Data represent the mean±SEM. Paired or unpaired Student t test, 1-way ANOVA (followed by the Newman-Keuls post test), or 2-way ANOVA (followed by an uncorrected Fisher least significant difference test) was used for statistical comparison between groups (Prism 5, GraphPad Software, La Jolla, CA). P values <0.05 were considered statistically significant.
Results
Cxcr7 Expression Patterns
Transcripts for both Cxcr7 and Cxcr4 were highly expressed in lung, spleen, and adipose tissue compared with liver and skeletal muscle ( Figure IA and IB in the online-only Data 
Conditional Cxcr7 Deletion Exacerbates Neointimal Hyperplasia
Ubiquitous deletion of Cxcr7 was induced in Apoe mice fed an HCD diet ( Figure 2D ), which indicates that the effect of CXCR7 is related to serum cholesterol levels. Apoe −/− mice showed markedly higher serum cholesterol levels than Apoe +/+ mice ( Figure 2E Figure 2F ). In contrast, the neointimal area, serum cholesterol and triglyceride levels, and peripheral monocyte counts in tamoxifen-treated Apoe −/− mice harboring 
CCX771 Ameliorates Neointimal Lesion Formation
To study the effect of a CXCR7 ligand in lesion formation, CCX771 (10 mg/kg) was injected into Apoe −/− mice, reaching mean CCX771 plasma levels of 336 ng/mL after 1 hour and 106 ng/mL after 12 hours ( Figure To study whether Cxcr7 expression in the spleen plays a role in the effect of CCX771 on neointima formation and hypercholesterolemia, splenectomized Apoe −/− mice were treated with CCX771 after vascular injury. However, even in the absence of the spleen, treatment with CCX771 reduced 
CCX771 Lowers Cholesterol Levels and Promotes VLDL Uptake in Adipose Tissue
To determine the role of CXCR7 in lipoprotein metabolism, lipoprotein profiles were analyzed in uninjured Apoe −/− mice fed an HCD after treatment with CCX771 or vehicle for 4 weeks. Treatment with CCX771 reduced serum cholesterol and triglyceride concentrations in fasting (5 hours) and nonfasting mice but did not affect the postprandial increase in cholesterol and triglyceride levels ( Figure 5A and 5B). The decrease in total serum cholesterol levels observed in CCX771-treated mice was caused by a reduced concentration of circulating VLDL cholesterol; however, LDL cholesterol and HDL cholesterol concentrations were unaltered by CCX771 ( Figure 5C ). In Ldlr −/− mice, treatment with CCX771 also reduced serum cholesterol and triglyceride levels after 4 weeks of an HCD compared with vehicle-treated controls ( Figure IX in the online-only Data Supplement).
To study the VLDL-lowering mechanism of CCX771, hepatic triglyceride secretion was analyzed by measuring ) fed a high-cholesterol diet and treated with CCX771 or vehicle 28 days after vascular injury (n=6 per group). Quantitative analysis of circulating monocytes (E; n=6-7 per group) and the ratio of Gr-1 hi to Gr-1 lo monocytes (F; n=4 per group) in mice treated with CCX771 or vehicle was performed 28 days after vascular injury. G and H, Splenectomized Apoe −/− mice fed a high-cholesterol diet were treated with vehicle or CCX771 for 28 days after vascular injury. Neointimal area in sections of the carotid artery (G; n=4 per group) and serum cholesterol levels (H; n=3-4 per group) were quantified. Representative images are shown. *P<0.05; **P<0.01. Scale bars, 200 μm.
by guest on April 20, 2017 http://circ.ahajournals.org/ Downloaded from the increase in serum triglyceride levels after injection of the lipase inhibitor P-407 (poloxamer 407). 22 At 6 hours after P-407 administration, triglyceride levels increased to similar levels in CCX771-and vehicle-treated mice (Figure X in the online-only Data Supplement). Accordingly, the hepatic triglyceride production rate was not altered by treatment with CCX771 ( Figure 5D ). To investigate the effect of CCX771 on VLDL clearance, DiI-labeled human VLDL was injected into Apoe −/− mice treated with CCX771 or vehicle for 4 weeks. At 60 minutes after injection of DiI-labeled VLDL, human apolipoprotein B100 and DiI levels in plasma were significantly reduced in CCX771-treated mice ( Figure 5E ), which indicates that CCX771 enhances the clearance of VLDL.
Next, DiI-labeled VLDL uptake was determined in VAT, brown adipose tissue, skeletal muscle, and liver of Apoe 
Effects of CCX771 on Adipose Tissue and Insulin Sensitivity
To study the mechanism of CXCR7-mediated uptake of VLDL, human Simpson-Golabi-Behmel syndrome (SGBS) adipocytes, which expressed CXCR7 as detected by immunostaining ( Figure XIII in the online-only Data Supplement), were treated with DiI-labeled VLDL. CCX771 significantly increased the basal uptake of DiI-VLDL compared with untreated, vehicletreated, or CCX704 (an analog of CCX771 with low affinity for CXCR7)-treated adipocytes ( Figure 6D ). Silencing of β-arrestin-2 with small interfering RNAs ( Figure 6E ) prevented the uptake of DiI-labeled VLDL triggered by CCX771 ( Figure 6F ), which indicates that β-arrestin-2 promotes VLDL uptake to adipocytes mediated by CXCR7.
To assess the effect of CCX771 on lipoprotein lipase (Lpl), which plays an important role in the clearance of VLDL, 23 lipase activity was determined in Apoe −/− mice after treatment with CCX771 or vehicle. Lipase activity was increased in VAT but not in plasma of CCX771-treated compared with vehicletreated mice ( Figure 7A ). Angptl3 and Angptl4 are negative regulators of Lpl activity. 24 Treatment with CCX771 reduced Angptl4 protein levels in VAT but not in plasma ( Figure 7B ), whereas Angptl3 protein levels were unaltered in the VAT and plasma in CCX771-treated compared with vehicle-treated mice ( Figure 7C) . Moreover, the Angptl4 mRNA expression level was diminished in the VAT of CCX771-treated mice, whereas expression of Lpl and Angptl3 transcripts remained unchanged ( Figure 7D ), which indicates that downregulation of Angptl4 may increase lipase activity in the VAT of CCX771-treated mice. In addition, the mRNA expression level of Pparg, a positive regulator of Angptl4 expression in adipocytes, was reduced in the VAT of CCX771-treated mice ( Figure 7D ). However, treatment with CCX771 did not substantially change the expression of Vldlr and Ldlr transcripts in the VAT ( Figure XIVA in the online-only Data Supplement). Unlike Cxcr4, the expression of Cxcr7 in different VATs was comparable to that in the spleen ( Figure XIVB in the onlineonly Data Supplement).
To determine the impact of CCX771 on insulin sensitivity, Apoe −/− mice were fed an HCD and treated with CCX771 or vehicle for 4 weeks. There was no significant difference in fasting and nonfasting blood glucose levels detectable between CCX771-treated and vehicle-treated mice ( Figure 7E ). Fasting insulin levels in the plasma were also similar between the groups ( Figure 7F) . Accordingly, the quantitative insulinsensitivity check index (QUICKI) was not different between Fasting and nonfasting serum cholesterol (A) and triglyceride (TG; B) concentrations were studied (n=4-5 per group). C, Total serum cholesterol and VLDL, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol were quantified by fast protein liquid chromatography (n=5-7 per group). D, TG production rate was calculated from serum TG concentrations before and 6 hours after treatment with poloxamer 407 (P-407; n=4 per group). E, Clearance of human apolipoprotein B100 (hApoB100) and DiI was studied at 3 minutes (control) and 60 minutes after intravenous injection of DiI-labeled VLDL (n=8-9 per group). *P<0.05. 
Treatment With CCX771 Inhibits Atherosclerosis
To investigate the role of CCX771 in diet-induced atherosclerosis, Apoe −/− mice fed an HCD were treated with CCX771 or vehicle for 12 weeks. The size of the atherosclerotic lesions in the aortic root ( Figure 8A ) and thoracoabdominal aorta ( Figure 8B ) and the number of Mac2 + macrophages in the aortic root lesions ( Figure 8C ) were reduced by CCX771. However, the number of SM22 + SMCs and the SM22 + area in the lesions were unaltered by CCX771 ( Figure 8D ), and serum cholesterol and triglyceride levels ( Figure 8E ), as well as the peripheral monocyte count ( Figure 8F ), were reduced. Alanine transaminase and creatinine levels ( Figure XV in the online-only Data Supplement) were comparable between CCX771-and vehicle-treated mice.
Discussion
The present results indicate a key role for CXCR7 in regulating lipoprotein metabolism and serum cholesterol levels in mice by enhancing the clearance of VLDL through adipose tissue under conditions of hyperlipidemia, thereby unveiling a new functional feature of chemokine receptors. Treatment with the CXCR7 ligand CCX771 reduced hyperlipidemia and subsequent monocytosis in Apoe −/− mice, thereby limiting atherosclerotic lesion formation. Thus, treatment with agents that activate CXCR7 appears to be a promising adjunct to lipidlowering drugs that are used to prevent atherosclerosis, especially in the context of metabolic disorders characterized by increased VLDL levels.
The neointimal accumulation of SMCs after vascular injury is mediated by the CXCL12-dependent recruitment of SPCs from the BM. 1, 8 CXCR4 is expressed on SPCs, and inhibition of CXCR4 or CXCL12 prevents neointima formation. 7, 8, 25 The present results did not indicate that CXCR7 ) fed a high-cholesterol diet and treated with CCX771 or vehicle for 28 days (n=4 per group). C, DiI-labeled VLDL (red) in epididymal adipose tissue from these mice was detected by in vivo multiphoton microscopy. D, DiI-labeled VLDL uptake to adipocytes was studied in untreated (Blank) and vehicle-, CCX704-, or CCX771-treated Simpson-Golabi-Behmel syndrome (SGBS) adipocytes. E, Expression of β-arrestin2 (ARRB2) mRNA in SGBS adipocytes treated with small interfering RNAs (siRNAs) against ARRB2 or nontargeting siRNAs (ctrl-siRNA). F, Effect of ARRB2 silencing on DiI-VLDL uptake to SGBS adipocytes treated with CCX771 or vehicle was determined. Data represent 3 independent experiments (D, E, and F). *P<0.05; ***P<0.001. Scale bars, 100 μm. ) were fed a high-cholesterol diet and treated with CCX771 or vehicle for 28 days. Lipase activity (A) and protein concentration of Angptl4 (B) and Angptl3 (C) were measured in plasma and VAT (n=4-5 per group). D, mRNA expression levels of Lpl, Angptl4, Angptl3, and Pparg were quantified in VAT (n=5-6 per group). E, Fasting and nonfasting blood glucose concentrations (E; n=4-6 per group) and fasting plasma insulin levels were determined (F; n=3-4 per group). G, As a surrogate marker for insulin sensitivity, quantitative insulin sensitivity check index (QUICKI) was calculated (n=3-4 per group). *P<0.05. regulates SPC mobilization or neointimal SMC accumulation. Although CXCR7 is not expressed on circulating leukocytes, 15 we found that a genetic deficiency of Cxcr7 results in enhanced neointima formation because of increased accumulation of Mac2 + macrophages. Alternatively, Mac2 (also known as galectin-3) may accumulate in the extracellular space after being released from macrophages 26 ; however, changes in lesional Mac2 + macrophage content correlate very well with those of F4/80 + macrophages, as determined by flow cytometry. 10 The increased macrophage accumulation can be explained by findings showing that the monocytosis induced by severe hyperlipidemia 3, 5 is aggravated in conditional Cxcr7 −/− Apoe −/− mice. In addition, hyperlipidemia may also promote the transformation of SMCs into foam cells and expression of the macrophage marker Mac2 in SMCs. 27 By contrast, neointima formation and monocyte counts were not altered in mildly hyperlipidemic Cxcr7 −/− mice, which indicates that the effect of CXCR7 on peripheral monocytes is indirect and dependent on the degree of hyperlipidemia. Concordantly, Cxcr7 deficiency further increased serum cholesterol levels only in HCD-fed Apoe −/− mice, which suggests a regulatory role for CXCR7 in lipid metabolism under severe hyperlipidemic conditions. Apoe itself controls hematopoietic stem cell proliferation (by autonomously promoting cholesterol efflux via ABC transporters), monocytosis, and lesional monocyte accumulation. 28 However, it is unlikely that CXCR7 directly compensates for such effects, because it is not expressed on BM cells. Although CXCR7 expression has been reported previously in lesional macrophages, 29 we did not detect CXCR7 in injured arteries, and genetic deletion of Cxcr7 in BM cells had no effect on neointima formation, which indicates a minor role of CXCR7 in macrophages during vascular repair.
Treatment of Apoe −/− mice with CCX771 led to the opposite phenotype to that expressed by Cxcr7 −/− mice in terms of lesion formation, monocytosis, and hyperlipidemia; this indicates that CCX771 triggers the activation of CXCR7. Of note, CCX771 induces stronger β-arrestin-2 activation via CXCR7 than its canonical ligand, namely, CXCL12. 16 In line with previous reports, we found that CXCR7 is expressed in cells within the marginal zone of the spleen, most likely in B cells, 13 which are involved in protective immunity against atherosclerosis. 30 However, removal of the spleen did not alter the effect of CCX771 on neointima formation and hyperlipidemia, which suggests that splenic CXCR7 expression does not play a role in atherosclerotic vascular disease. In contrast to neointima formation, both Cxcr7 −/− and CCX771-treated mice showed increased CXCL12 levels in the plasma and BM, which indicates that the endocytotic removal of CXCL12 is impaired by Cxcr7 deficiency and by CCX771 treatment. This parallel increase in CXCL12 levels in the plasma and BM maintained the gradient of CXCL12 between these 2 compartments, which prevented the mobilization of SPCs. 10 However, this effect on extracellular CXCL12 levels cannot explain the contrary change in neointima formation in Cxcr7 −/− and CCX771-treated mice.
The type of dyslipidemia observed in Apoe −/− mice is characterized by an elevation of VLDL/intermediate-density lipoprotein-derived cholesterol levels, whereas LDL cholesterol levels are only mildly increased and HDL cholesterol levels are reduced. 31 Treatment with CCX771 lowered only circulating VLDL levels in Apoe −/− mice by enhanced VLDL clearance and uptake to VAT, which is the primary storage site for unesterified cholesterol. [32] [33] [34] Cholesterol uptake by adipocytes occurs mainly via triglyceride-rich lipoproteins, such as chylomicrons and VLDL. 35 CCX771 treatment enhanced the uptake of cholesterol from VLDL to the VAT in a β-arrestin-2-dependent manner, which may explain the reduced serum cholesterol levels observed in CCX771-treated mice. Moreover, CCX771 treatment enhanced lipase activity in adipose tissue, presumably by downregulating Angptl4, which inhibits the lipolytic activity of Lpl by converting the active dimer into an inactive monomer. 36 In addition to lipolysis, Lpl dimers enhance the cellular uptake of VLDL independent of its catalytic activity by bridging between lipoproteins and lipoprotein receptors or proteoglycans. 37, 38 Increased Lpl activity may cause the reduced VLDL cholesterol and triglyceride serum levels in Angptl4 −/− mice, [39] [40] [41] and Apoe −/− mice lacking the Angptl4 gene develop less atherosclerosis. 39 Conversely, overexpression of Angptl4 impairs the clearance of VLDL and results in hypertriglyceridemia and hypercholesterolemia in mice. 41, 42 Moreover, chronic intermittent hypoxia increases VLDL levels, reduces adipose Lpl activity, and promotes atherosclerosis by upregulating Angptl4 expression in adipose tissue of Apoe −/− mice. 43 However, Angptl4 can also limit lipid accumulation in macrophages, which may play a role in the protection against atherosclerosis in mice that overexpress Angptl4. 44 In summary, these data indicate that activation of CXCR7 under hyperlipidemic conditions lowers Angptl4 expression in adipose tissue and thereby reduces serum cholesterol levels through enhanced Lpl-mediated uptake of VLDL to adipose tissue.
Taken together, these results suggest a novel role for the chemokine receptor CXCR7 in the uptake of VLDL into adipose tissue in Apoe −/− mice, which regulates serum cholesterol levels. Activation of CXCR7 by the synthetic ligand CCX771 protects against atherosclerosis, most likely by lowering serum lipid levels. Thus, treatment with CCX771 might be a promising therapeutic approach to treating atherogenic dyslipidemia. Cxcr7 flox mice. 
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CLINICAL PERSPECTIVE
Hypercholesterolemia caused by increased plasma levels of apolipoprotein B-containing lipoproteins, such as low-density lipoprotein or very low-density lipoprotein, drives the pathogenesis of atherosclerosis. Chemokines and their receptors mediate the hypercholesterolemia-induced mobilization and recruitment of monocytes that leads to accumulation of macrophages in atherosclerotic arteries. In contrast to other chemokine receptors, CXCR7 does not induce G-protein-coupled signaling and is not expressed on leukocytes but internalizes and degrades its ligands, such as CXCL12 and CXCL11. We studied the role of CXCR7 and the synthetic CXCR7 ligand CCX771 in mouse models of atherosclerosis. Our results reveal an unanticipated role of CXCR7 in the regulation of circulating very low-density lipoprotein cholesterol levels, which is unrelated to its effects on systemic CXCL12 levels. Treatment with CCX771 lowered very low-density lipoprotein levels in hyperlipidemic mice because of an enhanced uptake into adipose tissue and thus reduced hyperlipidemia-induced monocytosis and atherosclerotic lesion formation. This effect of CCX771 was probably attributable to increased lipoprotein lipase activity in adipose tissue in response to downregulation of Angptl4. Conversely, genetic deficiency of CXCR7 increased serum cholesterol and triglyceride levels and promoted lesion formation after vascular injury in hyperlipidemic mice. Thus, our findings indicate that adipose tissue regulates serum cholesterol levels under hyperlipidemic conditions through CXCR7-mediated uptake of very low-density lipoprotein. This cholesterol-buffering mechanism of adipose tissue may play an important role in the handling of an increased dietary lipid load. Pharmacological activation of CXCR7 can enhance its lipid-lowering effect and may thus provide a novel therapeutic approach to the treatment of atherogenic dyslipidemia.
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Supplemental Methods
X-gal staining
The Cxcr7 promoter activity was determined in Cxcr7 +/LacZ and Cxcr7 +/+ mice by X-gal staining. After perfusion with 10 ml of 2% PFA, tissues were removed and post-fixed for 15 min in 2% PFA on ice, washed with PBS containing 2 mM MgCl 2 , and then incubated in 5 staining solution (5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl 2 , 0.02% Nonidet P-40, 0.01% sodium deoxycholate, and 1 mg/ml X-gal [Life Technologies GmbH, Darmstadt, Germany; dissolved in dimethylformamide] in PBS) overnight at 37°C.
Subsequently, the fixed tissues were frozen and embedded in Tissue-Tek® O.C.T. compound (Sakura Finetek Germany GmbH, Staufen, Germany) for cryosectioning. Cryosections were 10 re-stained with the staining solution and nuclei were counterstained with Nuclear Fast Red (Vector Laboratories Inc., Burlingame, CA, USA).
Flow cytometry
To quantify murine Sca-1 + Lin -cells, peripheral blood cells were treated with phycoerythrin (PE)-conjugated anti-mouse Sca-1 (Ly-6A/E) (clone D7, CA: 12-5981; eBioscience, 15
Frankfurt, Germany) and the biotinylated anti-mouse hematopoietic lineage antibody panel (CD3, CD45R, CD11b, Ter-119, Ly-6G; eBioscience) followed by a Streptavidin-PE-Cy7 conjugate (eBioscience). Murine monocyte subtypes were studied by incubating peripheral blood cells with biotinylated anti-mouse CD3, CD45R, or Ter-119 antibodies (eBioscience), followed by incubation with a Streptavidin-PE-Cy7 conjugate (eBioscience), a PE-conjugated 20 antibody against CD115 (Clone AFS98, eBioscience), or a Cy TM 5.5-conjugated Gr-1 antibody (clone RB6-8C5, BD Biosciences, Heidelberg, Germany). To study Cxcr7 expression, cell suspensions were stained with a Cxcr7 antibody conjugated with PE-Cy7
(clone 8F11-M16; BioLegend, Fell, Germany). Cell suspensions derived from Cxcr7 -/-mice and isotype control antibodies were used as negative controls. To measure murine Lin -Sca-1 + CD34 + CD117 + endothelial progenitor cells (EPCs) 1, 2 , peripheral blood cells were incubated after erythrocyte lysis with AlexaFluor-647-conjugated anti-mouse CD34 (BD Biosciences), a PE-conjugated anti-mouse CD117 (BD Biosciences), and the biotinylated anti-mouse hematopoietic lineage antibody panel followed by a Streptavidin-PE-Cy7 conjugate. 5
Data were collected using a flow cytometer (FACSCanto™ II; BD Biosciences) and analyzed using FlowJo software (TreeStar, Inc., Ashland, USA).
Blood chemistry and hematology
Serum samples were analyzed by dry chemistry using a Vitros 250 Analyzer (Ortho Clinical Diagnostics GmbH, Neckargemünd, Germany) to determine the levels of cholesterol, 10 triglycerides, creatinine, alanine transaminase (ALT) or aspartate transaminase (AST). The peripheral blood count was determined using a hematology analyzer and EDTAanticoagulated blood (MEK-6450K, Nihon Kohden, Rosbach v.d.H., Germany).
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from murine tissues using an RNeasy micro or mini kit (Qiagen) 15 and reverse transcribed into cDNA using a Quantitect reverse transcription kit (Qiagen).
Primer sets specific for murine Cxcr7, Cxcr4, Angptl3, Angptl4, Vldlr, Ldlr (all Quantitect primer assay; Qiagen), Lpl (sense 5'-AGAGAGAGGACTCGGAGACG-3' and antisense 5'-AACTCAGGCAGAGCCCTTTC-3'), and Pparg (sense 5'-TTCAGAAGTGCCTTGCTGTG-3' and antisense 5'-CCAACAGCTTCTCCTTCTCG-3') were used for PCR amplification 20 (Quantitect SYBR green PCR kit; Qiagen) in a real time cycler (Opticon; Bio-Rad Laboratories GmbH, Munich, Germany). Gapdh, β-actin, and rpl13a were used as reference genes. Total RNA was extracted from human SGBS adipocytes using (mirVana miRNA isolation kit, Life technologies) and reverse transcribed using (High Capacity cDNA Reverse Transcription kit, Life technologies). The ARRB2 qRT-PCR assay was performed with a QuantiTect Primer assay and the QuantiTect SYBR green PCR kit (Qiagen) on a 7900HT RT-PCR system (Life technologies). Human GAPDH (sense 5'-CCATGGAGAAGGCTGGGG-3' and antisense 5'-CAAAGTTGTCATGGATGACC-3') was used as reference gene. 5
Qbase
PLUS software was used for data analysis (Biogazelle NV, Zwijnaarde, Belgium). Subcutaneous (SAT), visceral (VAT), and brown adipose tissue (BAT) were interactively segmented using the Imalytics Preclinical software (Philips, Aachen, Germany). Abdominal VAT was discriminated from SAT by the abdominal muscles. An iodine map was generated for the segmentation of interscapular BAT according to the accumulation of the contrast agent. The fat mass was calculated from the fat volume using a density of 0.92 g/cm 3 4 . 15
Micro-computed tomography (CT)
Lipoprotein separation by FPLC and measurement of cholesterol levels
Different lipoprotein fractions (VLDL, LDL, and HDL) were separated from the plasma using a Äkta FPLC system (GE Healthcare GmbH, Solingen, Germany) equipped with a Superose 6 10/300 column (GE Healthcare) and PBS as the running buffer. The cholesterol concentration 20 in the lipoprotein fractions was determined using a cholesterol assay kit (Cayman Europe, Tallinn, Estonia).
Quantification of DiI and cholesterol concentration in murine tissues and plasma
Apoe
-/-mice were fed a HCD and treated with CCX771 or vehicle (10% Captisol) for 4 wk.
Human DiI-VLDL (50 µg/mouse, Kalen Biomedical, Montgomery Village, USA) was injected intravenously to fasting (5 h) mice 2 h after the last administration of CCX771 or vehicle 5 . Blood samples were obtained at 3 and 60 min after the injection of DiI-VLDL. 5
Moreover, VAT, BAT, liver, and skeletal muscle were harvested 60 min after injection of DiI-VLDL and perfusion with PBS. Tissues were homogenized in cell lysis buffer (Cell signaling Technology, Inc., Danvers, USA) using a TissueLyser LT homogenizer (Qiagen).
The DiI fluorescence intensity was measured in the tissue homogenates (excitation wavelength: 514 nm; emission wavelength: 565 nm) and plasma using a microplate reader 10 (Infinite M200, Tecan). A standard curve was generated using different concentrations of DiI-VLDL. The cholesterol concentration was determined after dissolving the lipids in assay buffer using a cholesterol assay kit (Cayman Europe). The DiI and the cholesterol concentration in the homogenates were normalized to the protein concentration in the samples. 15
Two-photon laser scanning microscopy (TPLSM)
Intact epididymal adipose tissue and carotid arteries were mounted in a perfusion chamber 60 min after the injection of DiI-VLDL (50 µg/mouse). The chamber was filled with Hanks' balanced salt solution (Gibco® HBSS, Life Technologies, Inc.) and the temperature was constantly maintained at 37ºC. The carotid arteries were perfused at a pressure of 60 mmHg 20 and nuclei were fluorescently labeled (Syto41 Blue fluorescent nucleic acid stain, 1:1000 for 30 min, Invitrogen, Karlsruhe, Germany). Adipose tissues (AT) were embedded in agarose gels (3% agarose in HBSS) and covered with a coverslip (0.17 mm thick) and imaged using the Fluoview FV1000-MPE multiphoton system (Olympus Deutschland GmbH, Hamburg,
Lipase activity
The lipase activity in the plasma and epididymal AT homogenates was determined in Apoe -/-mice that were fed a HCD and treated with CCX771 or vehicle for 4 weeks using a lipase activity assay kit (Cayman Chemical Company, Ann Arbor, USA). Fluorescence intensities were measured every minute for 15 min at an excitation wavelength of 385 nm and an 5 emission wavelength of 515 nm using a microplate reader (Tecan). The lipase activity in the AT was standardized to the protein concentration.
Hepatic triglyceride production rate
The hepatic TG production rate was determined following injection of Poloxamer 407 (P-407, a gift from BASF ChemTrade GmbH, Germany) 6 . Apoe -/-mice were fed a HCD and treated 10 with CCX771 or Captisol for 4 weeks. Following this treatment, P-407 (0.5 mg/g BW, IP) was injected to fasting mice. Blood samples were collected directly before and 6 hours after the injection of P-407. The plasma triglyceride concentration was determined using a triglyceride colorimetric assay kit (Cayman Europe, Tallinn, Estonia). The TG production rate was calculated from the difference in plasma TG concentrations over the 6 h interval 15 following detergent injection and was expressed as µmol/kg BW/h using a plasma volume of 35 ml/kg BW 6 .
Index of insulin sensitivity and resistance
The quantitative insulin sensitivity check index (QUICKI) 7 was determined as a surrogate measure of insulin resistance. The QUICKI was calculated according the formula QUICKI = 20 1/[log(I 0 ) +log(G 0 )], where I 0 is the fasting plasma insulin (µU/mL), and G 0 is the fasting plasma glucose (mg/dl). Apoe -/-mice were fed a HCD and treated daily with CCX771 or vehicle for 4 wk. Fasting (5 h) blood samples were collected 2 h after the last injection. To assess postprandial glucose levels, non-fasting blood was drawn before the fasting period. In Illinois, USA), respectively.
Cell culture
Human SGBS preadipocytes (courtesy provided by Dr. Wabitsch) were cultured and differentiated as previously described 8 . 
